Calcineurin splicing variant calcineurin A{beta}1 improves cardiac function after myocardial infarction without inducing hypertrophy

Leanne Felkin, Takuya Narita, Renee Germack, Yasunori Shintani, Kunihiko Takahashi, Padmini Sarathchandra, Marina Lopez-Olaneta, Jesus Gomez-Salinero, Ken Suzuki, Paul J R Barton, Nadia Alicia Rosenthal, Enrique Lara-Pezzi

Research output: Contribution to journalArticleResearchpeer-review

44 Citations (Scopus)

Abstract

Backgrounda??Calcineurin is a calcium-regulated phosphatase that plays a major role in cardiac hypertrophy. We previously described that alternative splicing of the calcineurin AI? (CnAI?) gene generates the CnAI?1 isoform, with a unique C-terminal region that is different from the autoinhibitory domain present in all other CnA isoforms. In skeletal muscle, CnAI?1 is necessary for myoblast proliferation and stimulates regeneration, reducing fibrosis and accelerating the resolution of inflammation. Its role in the heart is currently unknown. Methods and Resultsa??We generated transgenic mice overexpressing CnAI?1 in postnatal cardiomyocytes under the control of the I?-myosin heavy chain promoter. In contrast to previous studies using an artificially truncated calcineurin, CnAI?1 overexpression did not induce cardiac hypertrophy. Moreover, transgenic mice showed improved cardiac function and reduced scar formation after myocardial infarction, with reduced neutrophil and macrophage infiltration and decreased expression of proinflammatory cytokines. Immunoprecipitation and Western blot analysis showed interaction of CnAI?1 with the mTOR complex 2 and activation of the Akt/SGK cardioprotective pathway in a PI3K-independent manner. In addition, gene expression profiling revealed that CnAI?1 activated the transcription factor ATF4 downstream of the Akt/mTOR pathway to promote the amino acid biosynthesis program, to reduce protein catabolism, and to induce the antifibrotic and antiinflammatory factor growth differentiation factor 15, which protects the heart through Akt activation. Conclusionsa??Calcineurin AI?1 shows a unique mode of action that improves cardiac function after myocardial infarction, activating different cardioprotective pathways without inducing maladaptive hypertrophy. These features make CnAI?1 an attractive candidate for the development of future therapeutic approaches.
Original languageEnglish
Pages (from-to)2838 - 2847
Number of pages10
JournalCirculation
Volume123
Issue number24
DOIs
Publication statusPublished - 2011

Cite this